A selection of injector pens for the Vegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, March 31, 2023.

Jim Wondruska | reuters

novo nordiskWeight Loss Blockbuster Injection veggie 1.5 million heart attacks, strokes and more could be prevented cardiac events in the US for more than 10 years, according to a Study Released this week.

Researchers at the University of California, Irvine also found that veggie This could result in fewer than 43 million Americans becoming obese in a decade. Notably, the study was partially funded by Novo Nordisk.

The results of the study complement initial data The Danish company revealed results last week from a large clinical trial that found Vegovy reduced the risk of serious heart problems and heart-related death by 20%.

Novo Nordisk’s trial studied overweight or obese patients with established heart disease, while the UC Irvine study examined similar patients, though without the disease.

Together, the results suggest that Vegovy and, potentially, similar obesity drugs have important health benefits beyond shedding unwanted pounds. Physicians and Wall Street analysts expect that to eventually put more pressure on insurers to cover obesity drugs that cost more than $1,000 a month.

“This is one of the biggest advances in the world of obesity and heart medicine,” said Nathan Wong, MD, who led the study and director of the Cardiovascular Disease Prevention Program in UC Irvine’s Department of Cardiology. “We now have a weight control therapy that also substantially reduces cardiovascular events beyond the diabetic population where it was originally studied.”

The researchers based their estimates on Novo Nordisk’s Phase 1 trial, which showed that Vegovy helped patients lose 15% of their body weight and also resulted in reduced cardiovascular risk factors.

The study estimated that 93 million US adults would meet eligibility criteria for the phase 1 trial, which studied people who were overweight or obese and excluded those with type 2 diabetes.

The researchers estimated that about half, or 43 million people, would not have obesity after treatment with Vagovi for 10 years.

An estimated 83 million Americans who do not have any established heart disease will experience heart health benefits after taking Vegovy for a decade.

Vegovy would reduce the risk of serious heart problems in that population by 17.8%, which means 1.5 million preventable heart attacks, strokes and other cardiovascular events.

The analysis did not estimate additional events that could be prevented in eligible adults with established heart disease.

Vegovy and Novo Nordisk’s diabetes drug Ozempic sparked a gold rush in the weight loss industry last year for helping patients shed unwanted weight. They are part of a class of drugs called GLP-1 agonists, which mimic hormones produced in the gut to suppress a person’s appetite.

But Novo Nordisk is grappling with a supply shortage that has led to shortages of both drugs.

there are also reports Patients who experienced thoughts of suicide and self-harm after taking Vegovy and other weight-loss drugs raised questions about the treatment’s unexpected and potentially life-threatening side effects.


Leave a Reply

Your email address will not be published. Required fields are marked *